Skip To The Main Content
Committee & Speaker Biographies

Committee & Speaker Biographies

2019 PDA Europe Pharmacopoeia

16-17 May 2019, Geneva, Switzerland

  • Susanne Keitel

    Susanne Keitel, PhD

    EDQM

    Dr. Susanne Keitel is a licensed pharmacist with a Ph.D. in pharmaceutical technology. Following ten years in the pharmaceutical industry, she held various senior positions at the Federal Institute for Drugs and Medical Devices (BfArM), Germany.

    Since October 2007, Susanne Keitel has held the post of Director of the European Directorate for the Quality of Medicine & HealthCare (EDQM), Council of Europe in Strasbourg.

  • Nadine Ritter

    Nadine M. Ritter, PhD

    Global Biotech Experts, LLC

    Nadine Ritter has been a protein scientist for over 30 years, with 10 years basic academic research in bone biology followed by 20+ years in biopharma CMC analytics.

    She received her BS in Biology/Chemistry from the University of Houston – Clear Lake, and her MA and PhD in Cell and Molecular Biology from Rice University, followed by an NIH postdoc at the University of Texas – Houston.

    Afterwards, she joined the biotech industry as a senior scientist at Abbott Laboratories for the development, validation, tech transfer and troubleshooting of protein analytical methods for a wide variety of proteins and peptides. Later, she became Director of Analytical Services at one of the first biopharma analytical CROs, BioReliance, where she managed contract R&D, GLP and cGMP laboratory operations in standard and state-of-the-art physiochemical and functional methods of analysis.

    In 2014, she launched Global Biotech Experts, a technical, regulatory and quality consultancy for biopharma products.

    For the last two decades, Nadine has been a writer, speaker and trainer in CMC analytical science and laboratory compliance for biotech products. She is on the Board of Directors of CASSS, and is a founding member of the CASSS CMC Strategy Forums. She is a member of the BioAB of PDA, and contributed to the PDA Method Qualification TR. She has been on the editorial board of BioProcess International from its inception, and has numerous publications on biotechnology analytical methods and laboratory quality practices.

    Nadine is frequently invited around the world to speak, consult and train for biotechnology product development, post-market changes, and compliance requirements for testing laboratories.

  • Vinny Browning

    Mervin Browning III, PhD

    Amgen

    As the QC Global Network Leader, QC Global Process Owner, and Director of the QC Center at Amgen, Inc., I am accountable for setting the overall QC Testing Strategy for the company and ensuring alignment from a regulatory perspective across QC. I am also responsible for our major computer related systems (LIMS, CDS, eCoA, and our e-notebook platforms), Raw Material Sampling and Inspection, and Compendia Compliance. I have held several different roles over my 21 year career, including Site Head of our Testing and Research Facility in the U.K., Director of QC Bioanalytics, Sr. Manager of Contract Testing, Critical Reagents, and Raw Materials Laboratories, as well as a QC Bioanalytical Testing Analyst. 

  • Frithjof Holtz

    Frithjof Holtz

    Merck KGaA

    Frithjof Holtz is a biologist and has been working for more than 28 years with Merck KGaA, Darmstadt, Germany, having years of experience in quality assurance and regulatory affairs. Besides experience in chemical manufacturing (excipients/APIs), he has also working experience in quality assurance for drug products (sterile/non-sterile).

    Furthermore, Frithjof has been working for more than 13 years in Regulatory Affairs (CMC) for pharmaceutical starting materials and consumables and their regulatory needs for their use in sterile/non-sterile drug product manufacturing and registration.

    Currently, he is responsible for the coordination of the advocacy & surveillance activities for Merck Life Science. In this role, he has gained additional expertise in regulations on sterile/biopharma drug substance/products. Besides this, Frithjof has many years of experience in working in industry associations as in Rx-360, APIC, EFCG, IPEC and PDA.

  • Falk Klar

    Falk Klar, PhD

    PDA Europe

    Falk Klar holds a PhD in Applied Physics and has more than 19 years of experience in Quality Assurance and Compliance. Before joining PDA Europe, he worked for the pharmaceutical, biopharmaceutical, and medical device industries, and in clinical research.

    Falk joined PDA Europe in 2015 as Senior Director Training & Education. He will develop and extend PDA Europe’s portfolio of training courses and workshops for the parenterals market. Recently, he was appointed General Manager and Vice President PDA Europe.

  • Ruth Miller

    Ruth K. Miller, JD

    PDA

    Ruth K. Miller is the Director of Regulatory Affairs for PDA. She manages the activities of PDA’s Regulatory and Quality Advisory Board, leading the team in shaping regulatory and policy documents globally. She is PDA’s primary point of communication with regulatory and policy bodies around the world.

    Before joining PDA, Ruth served in legal and regulatory roles covering the entire scope of the pharmaceutical supply chain. She was the Senior Director of Regulatory Affairs for a drug wholesaler trade association, working to impact U.S. federal and state regulations relating to the safe movement of pharmaceuticals, foods, and medical devices. She also has served as a regulatory and administrative law attorney in the U.S. Drug Enforcement Administration (DEA) Office of Chief Counsel; as Senior Counsel for the U.S. Pharmacopeia; and as an Associate in the food and drug practice of Covington & Burling, LLP, in the law firm’s Washington and London offices.

    Ruth holds a BA from The College of William and Mary in Virginia and a JD magna cum laude from the Boston University School of Law, where she was Executive Editor of the American Journal of Law and Medicine.

  • Paolo Tozzi

    Paolo Tozzi

    Novartis

    Paolo Tozzi’s career in the biopharmaceutical industry has spanned more than 18 years. So far, he has held positions of increasing responsibility in manufacturing quality including roles in validation, compliance, operations, and technology transfer.

    Currently, he is serving a dual role as Head of Pharmacopoeia Affairs and as a Global Program Manager for AS&T projects.

    Paolo received his MS in Pharmaceutical Chemistry and Technology from Siena University (Italy).

  • Joe Albanese

    Joseph Albanese, PhD

    Janssen J&J

    Joseph Albanese, Ph.D. holds a doctoral degree in Chemistry from the University of Delaware, Newark Delaware. 

    Dr. Albanese has more than 25 years of pharmaceutical industry and managerial experience. He is currently the Director of Analytical Strategy and Compliance in the Small Molecule Pharmaceutical Development department of Janssen Research and Development, LLC.  Joe is a member of the Small Molecule Analytical Development Leadership Team with oversight of regulatory intelligence that impact developmental and commercial products. 

    Joe  is the single point of contact for China projects such as Pharmacopoeia, Product Importation, and Generic Consistency Evaluation. He is defining a strategy to ensure all projects in development or commercialized products will comply to key emerging markets regulations for analytical development and developmental stability. He is also responsible for the compendial vigilance process for all Janssen ensuring compliance with US, European, Japanese, British, Chinese, Indian, and Russian pharmacopoeias. 

  • Ando Tsuyoshi

    Tsuyoshi Ando, PhD

    PMDA, Japanese Pharmacopeia

    Dr. Ando currently holds the position of Director, Division of Pharmacopoeia and Standards for Drug, Office of Review Management at the PMDA.

    His primary function is to manage the secretariat committee of Japanese Pharmacopeia (JP). Specific responsibilities include managing the secretariat of committee of JP and the PMDA’s technical activities in the Pharmacopeial Discussion Group (PDG), and also collaborating with WHO through the International Meeting of the World Pharmacopeias.

    Previously, he worked for PMDA as Review Director of Office of Drug IV, Review Director of Medical Devices III, Deputy Secretariat Director of Office of Review Innovation, Deputy Manager of Office of Review Management Pharmaceutical Affairs Consultation Group on R&D Strategy, Reviewer of Office of Biologics I, and also joined ICH-S7B (Expert) and ICH-Q11 (Topic Leader).

    He holds a Ph.D. in Pharmacology from Tokyo University of Pharmacy and Life Science.

     

  • Matthew Borer

    Matthew Borer, PhD

    Eli Lilly and Company

    Dr. Matthew Borer obtained his Ph.D. in Analytical Chemistry from Indiana University, Bloomington. He has since then dedicated his career to pharmaceutical analytical chemistry, including expertise in areas such as reference standards, compendial affairs, analytical method development, establishing pharmaceutical control strategies, statistical design of experiments, and technical leadership.

    After 26 years of experience in various pharmaceutical research and development roles, Dr. Borer is currently the senior technical and strategic leader for the global reference standard program at Eli Lilly and Company. In this role, he is responsible for all corporate reference standard materials that support drug development and manufacturing. He also is a technical consultant for the Lilly Compendial Affairs department, building relationships with global pharmacopoeia agencies and developing technical strategies associated with compendial compliance.

    Dr. Borer is an active volunteer at the United States Pharmacopeia, serving as Chair of the 2010-2015 Reference Standard Expert Committee and Chair of the 2015 - 2020 Joint Standards Setting Subcommittee on Chemical Medicines Reference Standards.

    Dr. Borer has been invited to speak at numerous global venues on a variety of analytical chemistry topics, including an emphasis on reference standards, compendial science and strategy, standardization of bioassay tests, and metal impurity testing.

  • Mihaela Buda

    Mihaela Buda, PhD

    EDQM

    Mihaela Buda is a Chemist with a Ph.D. in Pharmaceutical Chemistry from the Ruprecht-Karls University of Heidelberg, Germany. Following post-doctoral research in the Institute for Pharmacy and Molecular Biotechnology at the University of Heidelberg, she joined the Institute for Reference Materials and Measurement (IRMM) of the Joint Research Centre (JRC), a Directorate-General of the European Commission (EC).

    During her time with the IRMM, she was responsible for the development and certification of reference materials for quality control and calibration in bioanalysis. In March 2013, Mihaela joined the European Directorate for the Quality of Medicines & HealthCare (EDQM) of the Council of Europe in Strasbourg.

    She is a Scientific Officer in the Biologicals Division of the European Pharmacopoeia Department, with responsibility for the scientific coordination of a number of working parties including Water for Pharmaceutical Use (WAT) and Dialysis Solutions (DIA) Working Parties.

  • Kevin Carrick

    Kevin Carrick, PhD

    United States Pharmacopoeia

    Kevin Carrick is the Director of Science & Standards in Global Biologics, USP.

    He leads a team that develops Documentary standards (Chapters and monographs) and Reference Standards that support biopharmaceutical quality assessment.

    Dr. Carrick and his team work with the five USP biologics Expert Committees, multiple Expert Panels, and internal and external laboratories on development of standards for diverse biopharmaceutical from proteins to cell therapies.

  • Graham Cook

    Graham Cook, PhD

    Pfizer

    Graham leads Pfizer’s Global Quality Intelligence and Compendial Affairs group. He is the chair of Efpia’s Technical Development Group (TDEG) and is the Efpia Topic Lead for ICH Q12 Product Lifecycle Management. He was appointed to the British Pharmacopoeia Commission in 2010 and chairs the MC2 Expert Advisory Group and AQbD Working Party.

    Between 2012-2018, he was Chairman of the ASTM International E55 Technical Committee developing pharmaceutical manufacturing standards and continues to serve as a member of the E55 Executive Committee. He is a past chair of Pfizer’s QbD Council, and previous roles include Technical Director supporting Wyeth Europa Manufacturing and External Supply, and Director Formulation Development for Wyeth Consumer Healthcare (Richmond, VA). Graham is a pharmacist with a Ph.D. in pharmaceutics.

  • Sabine Kopp

    Sabine Kopp, PhD

    WHO

    Sabine Kopp was, inter alia, Secretary for the International Nonproprietary Names (INN) Programme, Acting Team Coordinator for Quality Assurance and Safety of Medicines, Programme Manager for the Quality Assurance and the Anticounterfeiting programmes, Acting Secretary of the International Medical Products Anti-Counterfeiting Taskforce (IMPACT) and was also actively involved in the WHO Member State mechanism on Substandard/spurious/falsely-labelled/falsified/counterfeit medical products. 

    Sabine Kopp is Secretary of the WHO Expert Committee on Specifications for Pharmaceutical Preparations and is responsible for the coordination of WHO's activities related to the development and maintenance of international guidelines, GXPs, standards and norms related to Medicines Quality Assurance and the International Pharmacopoeia, i.e. the normative work related to Medicines Quality Assurance within WHO, spanning from development and manufacturing to the distribution and supply of the medicines. She is overseeing WHO’s External Quality Assurance Assessment Scheme for quality control laboratories, serving as Secretary the international meetings of world pharmacopoeias and involved in WHO activities aimed at enabling synergies and convergence in medicines quality assurance.

  • Gina Marsee

    Gina Marsee

    Merck MSD

    Gina Marsee is the Director, Compendial Compliance and Advocacy at Merck located in West Point, PA, USA. Gina holds a Bachelor’s degree with majors in Chemistry & Biology from the University of Tennessee, Knoxville. She has worked in the pharmaceutical industry for 29 years holding various leadership roles within Quality, Compliance, and Regulatory Affairs teams.

    Prior to joining Merck, she was Site Head of Quality and Regulatory Affairs at Thermo Fisher Scientific/legacy Patheon (API) manufacturing facility in Greenville, SC.

    She previously worked at Pfizer/legacy Wyeth where she was engaged with various Compendial, Quality and Regulatory Policy efforts.

    Gina has served as a Delegate to the USP Convention, sitting on the Convention Governance & Expert Nominating Committees (2010-2015 cycle).

    Gina has served as a member of IPEC-America’s Executive Board and past Educational Program Chair for the IPEC ExcipientFest Conference.

    She is actively involved with European Federation of Pharmaceutical Industries and Associations (EFPIA), New Jersey Pharmaceutical Quality Control Association (NJPQCA), and Parenteral Drug Association (PDA) groups fostering engagement between industry and the various Pharmacopoeia.

  • Riviane Matos Goncalves

    Riviane Matos Gonçalves, MSc

    Brazilian Health Regulatory Agency

    Riviane Matos Gonçalves graduated in Pharmacy with an emphasis on Food Biochemistry from the University of Minas Gerais and subsequently obtained a Master’s degree in Pharmaceutical Sciences from the University of Brasília.

    She is a Health Regulation Specialist and has worked at the Brazilian Health Regulatory Agency (Anvisa) since 2005.

    She joined The Brazilian Pharmacopoeia in 2014. Since then, she has worked in the department of the Brazilian Pharmacopoeia Coordination in Anvisa.

    Riviane is currently a member of The Brazilian Nonproprietary Name Expert Committee of Brazilian Pharmacopoeia (CTT DCB) and offers executive support to The Pharmacognosy1 and The Herbal Medicines2 Expert Committees.

    1 Expert Committee responsible for chapters and monographs on Herbal Medicines in The Brazilian Pharmacopoeia

    2 Expert Committee responsible for the National Formulary on Herbal Medicines and The National Memento on Herbal Medicines

  • Aoife Mee

    Aoife Mee

    Novartis

    Aoife Mee is currently working as a specialist Project Lead for the reference standards program in Novartis.

    Aoife joined Novartis in 2007 and held various positions of increasing responsibility in QA/ QC including roles in stability, compliance and operations.

    In 2015, she joined the Novartis in-house reference standards program as team lead at the analytical services centre in Cork, Ireland and since then has been developing her expertise in reference standards qualification and quality systems for standards management.

    Since 2018, Aoife has led a global project for reference standards in Novartis, leveraging the expertise across the company to establish an enterprise Reference Standards Expert Network to drive harmonization of processes and procedures and best practice sharing within the company.

    Aoife graduated with a BSc in Biochemistry from University College Cork (Ireland).

  • James Pound

    James Pound

    MHRA

    James Pound joined the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in 2008. He has worked in a variety of roles within the British Pharmacopoeia (BP) & Laboratory Services Group and in 2017 was promoted to the role of Group Manager and Secretary & Scientific Director of the BP Commission.

    He is a senior leader within the Agency and has responsibility for both the pharmacopoeia and the Agency’s regulatory laboratory testing activities.

    He holds an honours degree in Chemistry and has previously worked in a variety of roles focused on analytical chemistry for both multinational pharmaceutical manufacturers and independent UK analytical laboratories.

  • Sandra Prior

    Sandra Prior, PhD

    NIBSC

    Dr. Sandra Prior joined NIBSC as Senior Scientist in 2015 working on the development of bioassay standards for therapeutic Monoclonal Antibodies (mAbs) and the investigation of structure-function in relation to the safety and efficacy of mAb products. She is also currently a member of the EDQM mAb working party expert committee. She has over 15 years’ experience in applied immunology and in vitro cell-based assay development. She obtained her PhD in 2000 from the University of Navarra (Spain) in collaboration with the Swiss Federal Institute of Technology (ETH-Zurich, Switzerland). Initially she worked in the field of bacterial vaccines investigating safety and protective mechanisms (NIBSC, Potters Bar, UK). In 2010, she joined Lonza Biologics (Cambridge, UK) where she worked as a Senior Scientist on bioactivity and immunogenicity assessment of biotherapeutics.

  • Andrew Rutter

    Andrew Rutter

    GSK

    As a Senior Director Primary Engineering Platforms, Andrew leads a team in GSK driven to change how existing and emerging technologies to transform manufacturing can be combined.

    As an Engineer, his career has taken him from Petrochemical Manufacture, via Techno-Economic Consulting, to Pharmaceutical Manufacture.

    His recent successes include delivery of a multistage continuous manufacture for one of GSK’s major products, reducing costs of manufacture whilst increasing precision.

  • Janeen Skutnik-Wilkinson

    Biogen

    Janeen has been in the pharmaceutical industry for nearly 20 years, with most of these positions being in a technical or regulatory support role. She has been very active on a number of pharmaceutical standards committees, chairing the IPEC for many years.

    Janeen’s current role is with Biogen in the US as Sr. Mgr Quality/cGXP Intelligence and Pharmacopoeial Affairs, where she uses her vast knowledge of the regulatory world and its processes to guide and advise on quality aspects of new and proposed pharmaceutical legislation.

  • Philip Travis

    Philip Travis

    Pfizer

    Philip Travis is Manager/Team Leader for Pfizer’s Compendial Affairs Group located in Parsippany, New Jersey, USA. He holds a BSc from the Pennsylvania State University.

    From 1996 to 2002, he was an analytical chemist supporting release testing for Excipients, Active Pharmaceutical Ingredients, and Drug Products.

    In 2002, he joined MSD’s Global Compendial Affairs Group. In 2004, he transitioned to Pfizer’s Compendial Affairs Group.

    Over the past 18 years, he has been extensively involved in the development and application of global Pharmacopoeial requirements. He has worked with industry and lead activities to promote the development of appropriate public standards through the European Federation of Pharmaceutical Industries and Associations; Consumer Healthcare Products Association, and New Jersey Pharmaceutical Quality Control Association.

    Philip chairs the USP Compendial Process Improvement Project Team.

  • Manisha Trivedi

    Manisha Trivedi, PhD

    Indian Pharmacopoeia Commission

    Manisha Trivedi is a licensed pharmacist, with a PhD in Pharmaceutical Sciences (India).

    She has been with the Indian Pharmacopoeia Commission since 2012 and has served in variety of scientific roles including scientific and regulatory compliance activities related to the development and maintenance of reference standards for active pharmaceutical ingredients and impurities included in Indian Pharmacopoeia. Drafting monographs, general chapters, method development as well as verification, she has also been providing hands on training for various analytical instruments to government analysts, drug inspectors, analysts of small and medium enterprises(SME) in pharma, research scholars, students and other international delegates.

    She is Deputy Quality Manager in the Reference Standard Division of IPC to ensure compliance with ISO 17025, ISO 17034 (Reference Material Producer) and ISO 17043 (Proficiency Testing Provider).

  • Jaap Venema

    Jaap Venema, PhD

    United States Pharmacopoeia

    Jaap Venema, Ph.D., is Executive Vice President and Chief Science Officer (CSO) for USP. He leads the organization’s scientific strategy and is responsible for the development of quality standards for medicines, dietary supplements, food ingredients and healthcare, including collaborations with other pharmacopeia and scientific groups.

    Dr. Venema guides USP’s exploration of emerging technologies that may inform future quality standards and oversees USP’s Up-to-Date program, which continuously evaluates and revises standards to reflect current and best practice. Dr. Venema also serves as Chair of the Council of Experts, spearheading USP’s work developing science-based standards. This body guides and approves the draft standards developed by USP’s numerous expert committees, comprised of nearly a thousand scientific experts from academia, industry, healthcare, as well as government agencies.

    A native of the Netherlands, Dr. Venema earned his Master’s degree in Chemistry from the Free University of Amsterdam, and his Ph.D. in Biochemistry and Molecular Biology from Leiden University in the Netherlands.

  • Cathy Vielle

    Cathie Vielle, PhD

    EDQM

    Mrs Cathie Vielle graduated in Pharmacy in 1996 from the University of Strasbourg. Since 1996 she has held several positions in QA compliance and in supply chain departments in an international pharmaceutical company.

    In September 2005, she became Head of Quality Department at a manufacturing site for worldwide markets (e.g. Europe, USA, Japan). She joined the EDQM in May 2009, as Head of the European Pharmacopoeia Department.

  • Mark Wiggins

    Mark Wiggins, PhD

    Global Pharmacopoeia Solutions LLC

    J. Mark Wiggins is Owner and Compendial Consultant with Global Pharmacopoeia Solutions LLC, which he formed after more than 30 years’ experience in the pharmaceutical industry.

    He is also Pharmacopoeia Editor for the on-line publication International Pharmaceutical Quality.

    He was previously Director of Compendial Affairs at Merck & Co., Inc., (known as MSD outside the US and Canada), with more than 15 years’ experience optimizing the processes for review and response to compendial changes from around the world to enable quality and regulatory compliance.

    Mr. Wiggins has been an active participant in compendial harmonization, represented PhRMA on ICH Q4B, authored several papers, and was an invited speaker at international meetings with pharmacopoeias and regulators in the US, UK, Europe, India, Japan, Korea, and China.